These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35760303)

  • 21. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant
    Zou C; Wei J; Shan B; Chen X; Wang D; Niu S
    Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
    Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
    Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE
    J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 26. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
    Gales AC; Stone G; Sahm DF; Wise MG; Utt E
    J Antimicrob Chemother; 2023 Jul; 78(7):1606-1615. PubMed ID: 37161662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
    Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.
    Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
    J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019.
    Jean SS; Lee YL; Hsu CW; Hsueh PR
    Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
    Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
    Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
    Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.